Tatiana Sergeevna Boldyreva
Research Subjects
Tatiana Sergeevna Boldyreva has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir Konstantinovich Lyadov
Russian Medical Academy of Continuous Professional Education
10 shared publications - Alexander Yuryevich Gorshkov
National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia
4 shared publications - Vsevolod Nikolaevich Galkin
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
4 shared publications - Denis Sergeevich Fedorinov
Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia
3 shared publications - Elena Vitalievna Zyatenkova
National Medical Research Center for Therapy and Preventive Medicine
3 shared publications - Mikhail Georgievich Chashchin
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation
3 shared publications
Latest Publications
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 56-61
Prophylactic embolization of the left gastric artery before neoadjuvant chemotherapy in gastric cancer patients
Transarterial embolization (TAE) is an effective method of hemostasis, but the prophylactic use of this procedure in patients with a high risk of bleeding remains poorly studied. Objective. To evaluate the clinical efficacy and safety of the left gastric artery TAE in patients with resectable gastric cancer and a history of gastrointestinal bleeding before neoadjuvant polychemotherapy (NAPCT). Material and methods. A single-center retrospective non-randomized study was conducted. Treatment results were analyzed in 14 patients (mean age 65±9 years) with resectable gastric cancer and a history of tumor bleeding, who underwent prophylactic embolization of the left gastric artery using microcoils or microspheres before NAPCT at the S.S. Yudin City Clinical Hospital from 2022 to 2024. The technical success of the procedure, the presence of bleeding recurrence and the tumor regression grade (TRG) were assessed. Results. TAE was technically successful in 12 patients (85.7%), of which 10 patients did not experience bleeding recurrence during NAPCT. Radical surgery was possible after successful TAE and NAPCT in 8 patients. There were 4 mild complications: post-embolization syndrome — 3, hematoma — 1. TRG according to Mandard classification constituted 1 — 1 case, 3 — 5 cases, 4 — 2 patients. Conclusion. Prophylactic embolization of the left gastric artery before NAPCT in patients with gastric cancer and tumor bleeding history is a clinically effective and safe procedure that can reduce the risk of bleeding recurrence and improve the tolerability of chemotherapy. However, further studies are needed to clarify the indications and evaluate the long-term results.
- 16 June 2026
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 15 (3) , 56-61
Prophylactic embolization of the left gastric artery before neoadjuvant chemotherapy in gastric cancer patients
Transarterial embolization (TAE) is an effective method of hemostasis, but the prophylactic use of this procedure in patients with a high risk of bleeding remains poorly studied. Objective. To evaluate the clinical efficacy and safety of the left gastric artery TAE in patients with resectable gastric cancer and a history of gastrointestinal bleeding before neoadjuvant polychemotherapy (NAPCT). Material and methods. A single-center retrospective non-randomized study was conducted. Treatment results were analyzed in 14 patients (mean age 65±9 years) with resectable gastric cancer and a history of tumor bleeding, who underwent prophylactic embolization of the left gastric artery using microcoils or microspheres before NAPCT at the S.S. Yudin City Clinical Hospital from 2022 to 2024. The technical success of the procedure, the presence of bleeding recurrence and the tumor regression grade (TRG) were assessed. Results. TAE was technically successful in 12 patients (85.7%), of which 10 patients did not experience bleeding recurrence during NAPCT. Radical surgery was possible after successful TAE and NAPCT in 8 patients. There were 4 mild complications: post-embolization syndrome — 3, hematoma — 1. TRG according to Mandard classification constituted 1 — 1 case, 3 — 5 cases, 4 — 2 patients. Conclusion. Prophylactic embolization of the left gastric artery before NAPCT in patients with gastric cancer and tumor bleeding history is a clinically effective and safe procedure that can reduce the risk of bleeding recurrence and improve the tolerability of chemotherapy. However, further studies are needed to clarify the indications and evaluate the long-term results.
- Open Access
Preoperative Cachexia as a Predictor of Postoperative Morbidity and a Target for Home-Based Prehabilitation in Resectable Gastric Cancer
Background: Gastric cancer (GC) is one of the most common malignancies, requires aggressive treatment, as has a high incidence of complications. The high prevalence of cachexia and comorbidity among GC patients has led to the development of the “prehabilitation” concept. We aimed to investigate the prognostic value of cachexia in the “Western” patient population with resectable GC and to evaluate its utility as an indicator for a home-based prehabilitation program. Methods: This cohort study included 147 patients who underwent surgical treatment for GC from 2019 to 2023. A multivariable analysis was conducted to study the impact of cachexia on postoperative outcomes in 122 patients with resectable GC. The prehabilitation group included 25 patients with cachexia who underwent a 2-week-long multimodal prehabilitation program prior to surgery. The functional results, as well as the 30-day incidence of postoperative complications and 90-day mortality, were evaluated. Results: There were 76 (51.7%) patients with cachexia. Multivariate analysis revealed that cachexia was a significant predictor of all postoperative complications (OR = 5.48, 95% CI 1.85–18.39, p = 0.001), severe postoperative complications (OR = 15.87, 95% CI 3.05–131.81, p < 0.001) and surgical site infection (SSI) (OR = 8.03, 95% CI 1.89–49.09, p = 0.038). Patients in the prehabilitation group had a lower incidence of SSI than in the control group (8.3% vs. 23.5%, p = 0.049). Conclusions: Preoperative cachexia is a potentially modifiable predictor of complications after gastric cancer surgery, and its identification may help define high-risk patients for proactive multimodal prehabilitation.
Open AccessPreoperative Cachexia as a Predictor of Postoperative Morbidity and a Target for Home-Based Prehabilitation in Resectable Gastric Cancer
Background: Gastric cancer (GC) is one of the most common malignancies, requires aggressive treatment, as has a high incidence of complications. The high prevalence of cachexia and comorbidity among GC patients has led to the development of the “prehabilitation” concept. We aimed to investigate the prognostic value of cachexia in the “Western” patient population with resectable GC and to evaluate its utility as an indicator for a home-based prehabilitation program. Methods: This cohort study included 147 patients who underwent surgical treatment for GC from 2019 to 2023. A multivariable analysis was conducted to study the impact of cachexia on postoperative outcomes in 122 patients with resectable GC. The prehabilitation group included 25 patients with cachexia who underwent a 2-week-long multimodal prehabilitation program prior to surgery. The functional results, as well as the 30-day incidence of postoperative complications and 90-day mortality, were evaluated. Results: There were 76 (51.7%) patients with cachexia. Multivariate analysis revealed that cachexia was a significant predictor of all postoperative complications (OR = 5.48, 95% CI 1.85–18.39, p = 0.001), severe postoperative complications (OR = 15.87, 95% CI 3.05–131.81, p < 0.001) and surgical site infection (SSI) (OR = 8.03, 95% CI 1.89–49.09, p = 0.038). Patients in the prehabilitation group had a lower incidence of SSI than in the control group (8.3% vs. 23.5%, p = 0.049). Conclusions: Preoperative cachexia is a potentially modifiable predictor of complications after gastric cancer surgery, and its identification may help define high-risk patients for proactive multimodal prehabilitation.
- Open Access
- 24 August 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (2) , 16-24
Cachexia and its impact on early postoperative results in patients with resectable gastric cancer
Background: Gastric cancer (GC) is one of the most common malignancies which requires aggressive combined treatment with a high incidence of complications. The search for modifiable risk factors or predictors of complications’ development is ongoing. We aimed to investigate the prognostic value of cachexia in patients with resectable GC. Materials and methods: A multi-center retro-prospective cohort study included data of 144 GC patients who underwent potentially curative gastrectomy between 2019 and 2023. Cachexia and sarcopenia were diagnosed according to the most recent consensus definitions. Сachexia was defined according to the international consensus criteria as the loss of ≥ 5 % of weight in 6 months or the loss of 2 % body weight in the presence of sarcopenia or BMI < 20 kg / m2. To assess the presence of sarcopenia we used Prado criteria (52.4 cm2 / m2 for men and 38.5 cm2 / m2 for women) and Martin criteria (41 cm2 / m2 for women and 43 cm2 / m2 for men with a BMI < 25 kg / m2 and 53 cm2 / m2 with a BMI > 25 kg / m2) for L3 skeletal-muscle index. The 30-day incidence of postoperative complications and 90-day mortality were evaluated. Results: There were 57 (39.5 %) patients with cachexia. Cachexia was more prevalent in patients with TNM stage III (42.1 % vs 24.1 %, p = 0.023) and sarcopenic patients (measured by skeletal muscle mass, 49.1 % vs. 18.3 %, p < 0.001, as well as dynamometry, 14.3 % vs. 0 %, p = 0.006). Multivariate analysis revealed that cachexia was a significant predictor of postoperative complications (ОR = 2.208, 95 % CI 1.051–4.638, p = 0.036) and surgical site infection (OR = 3.916, 95 % CI 1.146–13.3874, p = 0.029). The 90-day mortality rate was higher among patients with cachexia (10.5 % vs. 2.3 %, p = 0.039). Conclusion: Preoperative cachexia is a potentially modifiable predictor of complications after gastric cancer surgery which may help to identify high-risk patients for proactive multimodal рrehabilitation.
- 24 August 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (2) , 16-24
Open AccessCachexia and its impact on early postoperative results in patients with resectable gastric cancer
Background: Gastric cancer (GC) is one of the most common malignancies which requires aggressive combined treatment with a high incidence of complications. The search for modifiable risk factors or predictors of complications’ development is ongoing. We aimed to investigate the prognostic value of cachexia in patients with resectable GC. Materials and methods: A multi-center retro-prospective cohort study included data of 144 GC patients who underwent potentially curative gastrectomy between 2019 and 2023. Cachexia and sarcopenia were diagnosed according to the most recent consensus definitions. Сachexia was defined according to the international consensus criteria as the loss of ≥ 5 % of weight in 6 months or the loss of 2 % body weight in the presence of sarcopenia or BMI < 20 kg / m2. To assess the presence of sarcopenia we used Prado criteria (52.4 cm2 / m2 for men and 38.5 cm2 / m2 for women) and Martin criteria (41 cm2 / m2 for women and 43 cm2 / m2 for men with a BMI < 25 kg / m2 and 53 cm2 / m2 with a BMI > 25 kg / m2) for L3 skeletal-muscle index. The 30-day incidence of postoperative complications and 90-day mortality were evaluated. Results: There were 57 (39.5 %) patients with cachexia. Cachexia was more prevalent in patients with TNM stage III (42.1 % vs 24.1 %, p = 0.023) and sarcopenic patients (measured by skeletal muscle mass, 49.1 % vs. 18.3 %, p < 0.001, as well as dynamometry, 14.3 % vs. 0 %, p = 0.006). Multivariate analysis revealed that cachexia was a significant predictor of postoperative complications (ОR = 2.208, 95 % CI 1.051–4.638, p = 0.036) and surgical site infection (OR = 3.916, 95 % CI 1.146–13.3874, p = 0.029). The 90-day mortality rate was higher among patients with cachexia (10.5 % vs. 2.3 %, p = 0.039). Conclusion: Preoperative cachexia is a potentially modifiable predictor of complications after gastric cancer surgery which may help to identify high-risk patients for proactive multimodal рrehabilitation.
- Open Access
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 80-85
Multimodal prehabilitation in patients with gastrointenstinal cancer and cachexia: results of pilot study
Background. Patients undergoing surgical treatment for gastrointestinal tumors often suffer from symptoms of cachexia and sarcopenia. Preoperative preparation, or “prehabilitation”, is a potentially effective new approach to managing these patients. Aim. To evaluate whether multimodal prehabilitation decreases postoperative complications and improves functional recovery in cachexic patients undergoing gastrointestinal cancer surgery, in comparison to usual clinical care. Materials and methods. This prospective cohort study included data on 36 patients who underwent surgical treatment for gastrointestinal cancer from 2022 to 2023 at our cancer hospital. Sarcopenia and cachexia were assessed preoperatively using modern international consensus criteria. Patients participated in remote comprehensive prehabilitation program which encompassed nutritional and psychological support and supervised exercise. After prehabilitation functional results were assessed. Also, the 30-day postoperative complication rate measured according to the Clavien–Dindo criteria as well as 30-day and 90-day mortality. Results. After prehabilitation, 24 (66.6%) patients showed a statistically significant decrease in 400 m walking time (p = 0.028); 25 (69.4%) patients gained weight from 0.5 to 6 kg (p 0.001). Conclusion. Multimodal remote prehabilitation can improve functional status in patients with gastrointestinal cancer and cachexia.
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 80-85
Open AccessMultimodal prehabilitation in patients with gastrointenstinal cancer and cachexia: results of pilot study
Background. Patients undergoing surgical treatment for gastrointestinal tumors often suffer from symptoms of cachexia and sarcopenia. Preoperative preparation, or “prehabilitation”, is a potentially effective new approach to managing these patients. Aim. To evaluate whether multimodal prehabilitation decreases postoperative complications and improves functional recovery in cachexic patients undergoing gastrointestinal cancer surgery, in comparison to usual clinical care. Materials and methods. This prospective cohort study included data on 36 patients who underwent surgical treatment for gastrointestinal cancer from 2022 to 2023 at our cancer hospital. Sarcopenia and cachexia were assessed preoperatively using modern international consensus criteria. Patients participated in remote comprehensive prehabilitation program which encompassed nutritional and psychological support and supervised exercise. After prehabilitation functional results were assessed. Also, the 30-day postoperative complication rate measured according to the Clavien–Dindo criteria as well as 30-day and 90-day mortality. Results. After prehabilitation, 24 (66.6%) patients showed a statistically significant decrease in 400 m walking time (p = 0.028); 25 (69.4%) patients gained weight from 0.5 to 6 kg (p 0.001). Conclusion. Multimodal remote prehabilitation can improve functional status in patients with gastrointestinal cancer and cachexia.
- Open Access
- 15 December 2024
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 1 (3) , 26-48
Effect of sarcopenic obesity on treatment results in patients with malignant tumors of the gastrointestinal tract: systematic review
Background. Tumors of the gastrointestinal (GI) tract are characterized by high morbidity and poor prognosis. Over the past decade, sarcopenia (skeletal muscle depletion), myosteatosis, sarcopenic obesity were all shown to have negative prognostic effect in patients with various GI malignancies. However, the role of sarcopenic obesity (SO) in patients with GI tumors remains controversial. We have summarized clinical trial data on the effect of SO on treatment results in patients with malignant GI tumors who underwent surgical and/or drug antitumor treatment.Materials and methods. Thisstudy was conducted in comliance with the Preferred Reporting Itemsfor Systematic Review and Meta-Analyses (PRISMA) guidelines. PubMed and Cochrane Library databases were searched for relevant original studies published between January 2009 and December 2022 reporting postoperative complication rate and mortality, long-term survival and chemotherapy toxicity in SO patients with GI cancers.Results. Twenty four studies with 9,601 patients were included. The percentage of SO patients ranged from 2.6 to 51 %. Due to significant heterogeneity of SO determination methods and varying threshold values, the association between SO and outcomes of interest was inconsistent. SO was significantly associated with development of major postoperative complications in six studies. In contrast, three studies did not show any effect of SO on postoperative complications. Only two studies demonstrated that the mortality rate was significantly higher among patients with SO compared to those without SO. Four studies using multivariate analysis showed statistically significant effect of SO on long-term survival, one study – on disease-free survival. However, three trials contradicted this finding and reported that SO was not a negative prognostic factor of long-term survival in GI cancer patients. Three studies investigating SO effect on the outcomes of drug antitumor treatment showed negative effect of SO on chemotherapy toxicity.Conclusion. There is considerable heterogeneity in methods used to define SO in the literature, and current data is limited. Standardized terminology and deeper understanding of sarcopenic obesity pathophysiology is needed to further understand the effect of obesity and sarcopenia on clinical trajectory of patients with GI cancer.
- 15 December 2024
- Published by Publishing House ABV Press in Supportive Therapy in Oncology
- Vol. 1 (3) , 26-48
Open AccessEffect of sarcopenic obesity on treatment results in patients with malignant tumors of the gastrointestinal tract: systematic review
Background. Tumors of the gastrointestinal (GI) tract are characterized by high morbidity and poor prognosis. Over the past decade, sarcopenia (skeletal muscle depletion), myosteatosis, sarcopenic obesity were all shown to have negative prognostic effect in patients with various GI malignancies. However, the role of sarcopenic obesity (SO) in patients with GI tumors remains controversial. We have summarized clinical trial data on the effect of SO on treatment results in patients with malignant GI tumors who underwent surgical and/or drug antitumor treatment.Materials and methods. Thisstudy was conducted in comliance with the Preferred Reporting Itemsfor Systematic Review and Meta-Analyses (PRISMA) guidelines. PubMed and Cochrane Library databases were searched for relevant original studies published between January 2009 and December 2022 reporting postoperative complication rate and mortality, long-term survival and chemotherapy toxicity in SO patients with GI cancers.Results. Twenty four studies with 9,601 patients were included. The percentage of SO patients ranged from 2.6 to 51 %. Due to significant heterogeneity of SO determination methods and varying threshold values, the association between SO and outcomes of interest was inconsistent. SO was significantly associated with development of major postoperative complications in six studies. In contrast, three studies did not show any effect of SO on postoperative complications. Only two studies demonstrated that the mortality rate was significantly higher among patients with SO compared to those without SO. Four studies using multivariate analysis showed statistically significant effect of SO on long-term survival, one study – on disease-free survival. However, three trials contradicted this finding and reported that SO was not a negative prognostic factor of long-term survival in GI cancer patients. Three studies investigating SO effect on the outcomes of drug antitumor treatment showed negative effect of SO on chemotherapy toxicity.Conclusion. There is considerable heterogeneity in methods used to define SO in the literature, and current data is limited. Standardized terminology and deeper understanding of sarcopenic obesity pathophysiology is needed to further understand the effect of obesity and sarcopenia on clinical trajectory of patients with GI cancer.
- Open Access
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 290-294
Remote pre-habilitation in patients with cachexia and resectable gastric cancer: a case series
Background. The high rate of functional impairment and nutritional deficiency in patients with localized and locally advanced gastric tumors led to the concept of "pre-habilitation". Multimodal pre-habilitation refers to a combination of physical therapy, nutritional support, and psychological counseling during the preparation of patients for antitumor treatment. Aim. To present the outcomes of patients with cachexia after the program of remote multimodal pre-habilitation before surgical treatment of gastric cancer. Materials and methods. The outcomes of 10 patients with resectable gastric cancer and cancer cachexia were analyzed. Patients underwent comprehensive preoperative preparation, including nutritional support, physical therapy, and remote psychological counseling. Results. There was an improvement in functional parameters: an increase in walking speed in 8 patients, an increase in hand grip strength measured by dynamometry in 7 patients, and an increase in exercise tolerance in 2 patients. No early or late postoperative complications were reported. Conclusion. Multimodal remote pre-habilitation is a promising option for preparing patients with cachexia for surgical treatment of gastric cancer.
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 290-294
Open AccessRemote pre-habilitation in patients with cachexia and resectable gastric cancer: a case series
Background. The high rate of functional impairment and nutritional deficiency in patients with localized and locally advanced gastric tumors led to the concept of "pre-habilitation". Multimodal pre-habilitation refers to a combination of physical therapy, nutritional support, and psychological counseling during the preparation of patients for antitumor treatment. Aim. To present the outcomes of patients with cachexia after the program of remote multimodal pre-habilitation before surgical treatment of gastric cancer. Materials and methods. The outcomes of 10 patients with resectable gastric cancer and cancer cachexia were analyzed. Patients underwent comprehensive preoperative preparation, including nutritional support, physical therapy, and remote psychological counseling. Results. There was an improvement in functional parameters: an increase in walking speed in 8 patients, an increase in hand grip strength measured by dynamometry in 7 patients, and an increase in exercise tolerance in 2 patients. No early or late postoperative complications were reported. Conclusion. Multimodal remote pre-habilitation is a promising option for preparing patients with cachexia for surgical treatment of gastric cancer.
- Open Access
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 278-282
Colon cancer-induced sarcopenia: clinical and radiological correlations
Background. The course of colon cancer (CC) is burdened in many patients with elderly and senile age, the presence of severe comorbidities, and complications of the malignancy. The complex treatment for advanced colon tumors also requires the search for predictors appropriate for routine clinical practice. Aim. To study the prevalence of sarcopenia (SP) in CC and assess the relationship of SP with the immediate treatment outcomes. Materials and methods. A retro-prospective assessment of cachexia and SP according to clinical and radiological criteria and their relationship to postoperative complications was performed in 679 patients. The mean age was 65±10.7 years. Group 1 included 181 patients who received drug therapy for common types of CC. Group 2 included 498 patients who underwent elective colon resections for cancer. The presence of SP was determined by threshold values for skeletal muscle area at the LIII level, averaged to the patient's height squared. To do this, the data from abdominal computed tomography performed for 1 month or less before the start of antitumor treatment were analyzed. The threshold criteria of Prado, Martin, and the European Working Group on Sarcopenia in Older People (EWGSOP2) were compared. Results. The SP prevalence was 64% according to the Prado criteria for stages I–II, 66% for stage III, and 73.4% for stage IV; according to the Martin criteria, 63.1%, 62.3%, and 68%, respectively, and according to the EWGSOP2 criteria 22.7%, 26.9%, and 32%, respectively. In general, SP was noted according to the Prado criteria in 70.2% of men and 61.4% of women, according to the Martin criteria in 55.8% of men and 71.9% of women, and according to the EWGSOP2 criteria in 27% of men and 22.9% of women. Sarcopenic obesity was identified in 10.1% of patients. In group 1, there was a statistically significant correlation (p0.001) between the presence of SP and poor overall survival of patients, with the Martin criteria showing the most significant correlation. In group 2, an equally strong correlation between the presence of SP according to the Prado criteria and postoperative mortality was found. Conclusion. In CC, SP is detected in more than half of patients before the start of antitumor treatment, being an unfavorable prognostic factor for overall survival and a predictor of death after surgical treatment. Timely diagnosis and treatment of SP can improve the CC therapy outcome.
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 278-282
Open AccessColon cancer-induced sarcopenia: clinical and radiological correlations
Background. The course of colon cancer (CC) is burdened in many patients with elderly and senile age, the presence of severe comorbidities, and complications of the malignancy. The complex treatment for advanced colon tumors also requires the search for predictors appropriate for routine clinical practice. Aim. To study the prevalence of sarcopenia (SP) in CC and assess the relationship of SP with the immediate treatment outcomes. Materials and methods. A retro-prospective assessment of cachexia and SP according to clinical and radiological criteria and their relationship to postoperative complications was performed in 679 patients. The mean age was 65±10.7 years. Group 1 included 181 patients who received drug therapy for common types of CC. Group 2 included 498 patients who underwent elective colon resections for cancer. The presence of SP was determined by threshold values for skeletal muscle area at the LIII level, averaged to the patient's height squared. To do this, the data from abdominal computed tomography performed for 1 month or less before the start of antitumor treatment were analyzed. The threshold criteria of Prado, Martin, and the European Working Group on Sarcopenia in Older People (EWGSOP2) were compared. Results. The SP prevalence was 64% according to the Prado criteria for stages I–II, 66% for stage III, and 73.4% for stage IV; according to the Martin criteria, 63.1%, 62.3%, and 68%, respectively, and according to the EWGSOP2 criteria 22.7%, 26.9%, and 32%, respectively. In general, SP was noted according to the Prado criteria in 70.2% of men and 61.4% of women, according to the Martin criteria in 55.8% of men and 71.9% of women, and according to the EWGSOP2 criteria in 27% of men and 22.9% of women. Sarcopenic obesity was identified in 10.1% of patients. In group 1, there was a statistically significant correlation (p0.001) between the presence of SP and poor overall survival of patients, with the Martin criteria showing the most significant correlation. In group 2, an equally strong correlation between the presence of SP according to the Prado criteria and postoperative mortality was found. Conclusion. In CC, SP is detected in more than half of patients before the start of antitumor treatment, being an unfavorable prognostic factor for overall survival and a predictor of death after surgical treatment. Timely diagnosis and treatment of SP can improve the CC therapy outcome.
- Open Access
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 266-272
Nutritional support in oncology: the place of parenteral nutrition (literature review)
Currently nutritional support is considered as one of the most important components of the treatment of cancer patients. This is due to the positive effect of correction of nutritional status on the course of the underlying disease, the tolerability of antitumor treatment, rehabilitation measures and quality of life. The most important principle of nutritional support is its continuity at all stages of the patient's curation: polyclinic, inpatient, rehabilitation. The purpose of the review was to discuss nutritional support for cancer patients with an emphasis on parenteral nutrition. Out of more than 120 initially selected literature sources from various databases (Scopus, Web of science, RSCI, etc.), 55 sources were left for analysis mainly over the past 5 years, earlier publications were used while maintaining their informativeness for clinicians. The modern concept of parenteral nutrition implies the appointment of drugs “three in one”. Parenteral nutrition should include not only macronutrients, but also micronutrients: fat- and water-soluble vitamins, ω-3 fatty acids. It has been established that the development of infectious complications with nutritional support is not related to its type, but to the calorie intake. The issues of additional parenteral nutrition with inadequate enteral nutrition are examined. The clinician should personalize nutritional support taking into account the type of tumor process, its stage, the characteristics of the patient and the severity of eating disorders. During the treatment of patients with oncological diseases, it is necessary to assess the state of their nutritional status and, if necessary, carry out correction. The doctor is obliged to choose the optimal way to provide the patient with energy and plastic materials – oral supplemental nutrition, enteral nutrition, parenteral nutrition or a combination of them. Clinical practice shows that the rejection of parenteral nutrition is accompanied by a decrease in the quality of nutritional support. The choice of the type of nutritional support is based on the indications for its implementation, which are detailed in the clinical recommendations. Strict adherence to the algorithm of correction of nutritional status depending on the stage of cancer, the patient's condition, the type of antitumor therapy will optimize the results of treatment and improve the quality of life.
- 10 December 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 25 (3) , 266-272
Open AccessNutritional support in oncology: the place of parenteral nutrition (literature review)
Currently nutritional support is considered as one of the most important components of the treatment of cancer patients. This is due to the positive effect of correction of nutritional status on the course of the underlying disease, the tolerability of antitumor treatment, rehabilitation measures and quality of life. The most important principle of nutritional support is its continuity at all stages of the patient's curation: polyclinic, inpatient, rehabilitation. The purpose of the review was to discuss nutritional support for cancer patients with an emphasis on parenteral nutrition. Out of more than 120 initially selected literature sources from various databases (Scopus, Web of science, RSCI, etc.), 55 sources were left for analysis mainly over the past 5 years, earlier publications were used while maintaining their informativeness for clinicians. The modern concept of parenteral nutrition implies the appointment of drugs “three in one”. Parenteral nutrition should include not only macronutrients, but also micronutrients: fat- and water-soluble vitamins, ω-3 fatty acids. It has been established that the development of infectious complications with nutritional support is not related to its type, but to the calorie intake. The issues of additional parenteral nutrition with inadequate enteral nutrition are examined. The clinician should personalize nutritional support taking into account the type of tumor process, its stage, the characteristics of the patient and the severity of eating disorders. During the treatment of patients with oncological diseases, it is necessary to assess the state of their nutritional status and, if necessary, carry out correction. The doctor is obliged to choose the optimal way to provide the patient with energy and plastic materials – oral supplemental nutrition, enteral nutrition, parenteral nutrition or a combination of them. Clinical practice shows that the rejection of parenteral nutrition is accompanied by a decrease in the quality of nutritional support. The choice of the type of nutritional support is based on the indications for its implementation, which are detailed in the clinical recommendations. Strict adherence to the algorithm of correction of nutritional status depending on the stage of cancer, the patient's condition, the type of antitumor therapy will optimize the results of treatment and improve the quality of life.
- Open Access
- 23 June 2023
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 13 (2) , 60-65
Multimodal prehabilitation in a patient with right colon cancer, frailty and severe sarcopenia: a case report
Background. The high frequency of frailty and sarcopenia in patients with cancer led to the development of «prehabilitation» concept. multimodal prehabilitation includes physical training, nutritional and psychological support before anticancer treatment.Aim. we aim to present the results of treatment of a patient with frailty and severe sarcopenia who underwent a multimodal prehabilitation program before surgery for colorectal cancer.Materials and methods. A 81-year-old woman with colon cancer was diagnosed with frailty and severe sarcopenia. The patient underwent a multimodal prehabilitation for 12 days prior to surgery, which included nutritional and psychological support as well as a supervised physical exercise program based on nordic walking.Results. The patient gained weight. Also, she increased grip strength and gait speed. The postoperative period went uneventfully and the patient was discharged home 7 days after surgery.Conclusions. multimodal prehabilitation is a potentially beneficial option in sarcopenic patients with frailty and colon cancer who need surgery.
- 23 June 2023
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 13 (2) , 60-65
Open AccessMultimodal prehabilitation in a patient with right colon cancer, frailty and severe sarcopenia: a case report
Background. The high frequency of frailty and sarcopenia in patients with cancer led to the development of «prehabilitation» concept. multimodal prehabilitation includes physical training, nutritional and psychological support before anticancer treatment.Aim. we aim to present the results of treatment of a patient with frailty and severe sarcopenia who underwent a multimodal prehabilitation program before surgery for colorectal cancer.Materials and methods. A 81-year-old woman with colon cancer was diagnosed with frailty and severe sarcopenia. The patient underwent a multimodal prehabilitation for 12 days prior to surgery, which included nutritional and psychological support as well as a supervised physical exercise program based on nordic walking.Results. The patient gained weight. Also, she increased grip strength and gait speed. The postoperative period went uneventfully and the patient was discharged home 7 days after surgery.Conclusions. multimodal prehabilitation is a potentially beneficial option in sarcopenic patients with frailty and colon cancer who need surgery.
- Open Access
- 1 February 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (4) , 464-467
Remote multimodal prehabilitation in the presence of cachexia and resectable gastric cancer: a clinical case
Background. The high frequency of cachexia and sarcopenia (skeletal muscle depletion) in patients with cancer led to the development of prehabilitation concept. Multimodal prehabilitation includes physical training, nutritional and psychological support before anticancer treatment. Aim. To present the results of treatment of a patient with cachexia who underwent a multimodal prehabilitation program before surgery for gastric cancer. Materials and methods. A 74-year-old woman with early stage cancer of the gastric antrum had lost 28% of total body weight in the previous 6 months because of a dysphoric disorder. The patient underwent a multimodal prehabilitation for 2 weeks prior to surgery, which included nutritional (600 ml siping per day) and psychological support as well as a supervised remote physical exercise program based on nordic walking. Results. The patient increased functional walking capacity from low to medium, grip strength and gait speed. The postoperative period went uneventfully and the patient was discharged home 8 days after surgery. Conclusion. Multimodal remote prehabilitation is a potentially beneficial option in cachectic patients with gastric cancer who need surgery.
- 1 February 2023
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 24 (4) , 464-467
Open AccessRemote multimodal prehabilitation in the presence of cachexia and resectable gastric cancer: a clinical case
Background. The high frequency of cachexia and sarcopenia (skeletal muscle depletion) in patients with cancer led to the development of prehabilitation concept. Multimodal prehabilitation includes physical training, nutritional and psychological support before anticancer treatment. Aim. To present the results of treatment of a patient with cachexia who underwent a multimodal prehabilitation program before surgery for gastric cancer. Materials and methods. A 74-year-old woman with early stage cancer of the gastric antrum had lost 28% of total body weight in the previous 6 months because of a dysphoric disorder. The patient underwent a multimodal prehabilitation for 2 weeks prior to surgery, which included nutritional (600 ml siping per day) and psychological support as well as a supervised remote physical exercise program based on nordic walking. Results. The patient increased functional walking capacity from low to medium, grip strength and gait speed. The postoperative period went uneventfully and the patient was discharged home 8 days after surgery. Conclusion. Multimodal remote prehabilitation is a potentially beneficial option in cachectic patients with gastric cancer who need surgery.